About towa pharm - TWAPF
Towa Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its products include neurological and anti-allergic drugs, cardiovascular and respiratory drugs, gastrointestinal drugs, antibiotics and chemotherapeutic drugs, vitamins, hormone drugs, and other metabolic drugs. It operates through Domestic and Overseas Segments. The Domestic segment manufacture and sale of pharmaceuticals directly to medical institutions through sales offices, as well as to agents, pharmaceutical wholesalers, and other pharmaceutical manufacturers. The Overseas segment engages in generic pharmaceutical sales business; contract research; and development and manufacturing business. The company was founded in June 1951 and is headquartered in Kadoma, Japan.
TWAPF At a Glance
Towa Pharmaceutical Co., Ltd.
2-11 Shinbashi-cho
Kadoma, Osaka 571-8580
| Phone | 81-6-6900-9100 | Revenue | 1.70B | |
| Industry | Pharmaceuticals: Major | Net Income | 124.54M | |
| Sector | Health Technology | 2025 Sales Growth | 8.027% | |
| Fiscal Year-end | 03 / 2026 | Employees | 4,788 | |
| View SEC Filings |
TWAPF Valuation
| P/E Current | 11.756 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 7.081 |
| Price to Sales Ratio | 0.518 |
| Price to Book Ratio | 0.768 |
| Price to Cash Flow Ratio | 5.75 |
| Enterprise Value to EBITDA | 7.465 |
| Enterprise Value to Sales | 1.246 |
| Total Debt to Enterprise Value | 0.728 |
TWAPF Efficiency
| Revenue/Employee | 355,641.174 |
| Income Per Employee | 26,010.629 |
| Receivables Turnover | 3.555 |
| Total Asset Turnover | 0.568 |
TWAPF Liquidity
| Current Ratio | 2.812 |
| Quick Ratio | 1.581 |
| Cash Ratio | 0.517 |
TWAPF Profitability
| Gross Margin | 36.491 |
| Operating Margin | 8.954 |
| Pretax Margin | 10.143 |
| Net Margin | 7.314 |
| Return on Assets | 4.155 |
| Return on Equity | 11.437 |
| Return on Total Capital | 4.626 |
| Return on Invested Capital | 5.177 |
TWAPF Capital Structure
| Total Debt to Total Equity | 134.586 |
| Total Debt to Total Capital | 57.372 |
| Total Debt to Total Assets | 49.059 |
| Long-Term Debt to Equity | 120.541 |
| Long-Term Debt to Total Capital | 51.384 |